Muhammad Shafi
Pulmonary Disease · Huntsville, ALNPI 1407298029
Payments from drug & device makers
Across 262 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Insmed, Inc.$632
- Sanofi$587
- Regeneron Healthcare Solutions, Inc.$387
- AstraZeneca$307
- Novartis$238
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,412100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 60 | $1,008 |
| Insmed, Inc. | 26 | $632 |
| Sanofi | 22 | $587 |
| Regeneron Healthcare Solutions, Inc. | 15 | $387 |
| AstraZeneca | 17 | $307 |
| Novartis | 13 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $216 |
| Boehringer Ingelheim | 8 | $216 |
| Grifols USA, LLC | 9 | $216 |
| Actelion Pharmaceuticals US, Inc. | 10 | $179 |
| United Therapeutics Corporation | 5 | $174 |
| Mylan Specialty L.p. | 7 | $169 |
| Avadel CNS Pharmaceuticals, LLC | 8 | $154 |
| Jazz Pharmaceuticals Inc. | 6 | $132 |
| Amgen | 7 | $132 |
| Axsome Therapeutics, Inc. | 7 | $117 |
| Electromed, Inc. | 8 | $93 |
| Inogen, Inc. | 5 | $90 |
| Baxter Healthcare | 4 | $70 |
| Verona Pharma, Inc. | 2 | $50 |
| Genentech USA, Inc. | 3 | $49 |
| Harmony Biosciences LLC | 2 | $40 |
| Philips North America LLC | 2 | $38 |
| Melinta Therapeutics, LLC | 2 | $38 |
| CSL Behring | 1 | $35 |
| Viatris Specialty LLC | 1 | $29 |
| Pfizer | 1 | $19 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$5,428 in reported general payments places this provider in the 55th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 342 | $261,259 |
| OfevNintedanib Esylate | 15 | $194,897 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 178 | $87,819 |
| Advair HfaFluticasone Propion/Salmeterol | 153 | $64,674 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 78 | $38,644 |
| Spiriva HandihalerTiotropium Bromide | 52 | $36,672 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 71 | $36,504 |
| Spiriva RespimatTiotropium Bromide | 56 | $35,225 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $25,543 |
| Incruse ElliptaUmeclidinium Bromide | 65 | $21,623 |
| SymbicortBudesonide/Formoterol Fumarate | 85 | $21,081 |
| Tiotropium Bromide | 44 | $21,020 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $17,192 |
| Pirfenidone | 16 | $12,086 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 537 | $11,905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $216 | $354,445320 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $1,008 | $345,152557 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $307 | $52,753136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Huntsville
- Luther CorleyHuntsville$86K
- Roshen MathewHuntsville$19K
- Murthy VuppalaHuntsville$16K
- Richard SneeringerHuntsville$14K
- Misbahuddin SiddiquiHuntsville$12K
- Saketh Palasamudram ShekarHuntsville$11K
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.